Kristine Peterson

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Mystic, CT
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
By: /s/ James Kastenmayer, Attorney-in-Fact for: Kristine Peterson
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Kristine Peterson

Form 4 holding Director

ImmunoGen, Inc.

Security class
Deferred Share Unit
Shares / value
0
Estimated value
$0
Report date
12 Feb 2024
Price
$29.30
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ImmunoGen, Inc.

Security class
Restricted Stock Unit
Shares / value
0
Estimated value
$0
Report date
12 Feb 2024
Price
$29.30
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

AMARIN CORP PLC\UK

Security class
Stock Option (Right to Buy)
Shares / value
115,919
Estimated value
Report date
27 Jun 2022
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

AMARIN CORP PLC\UK

Security class
Restricted Stock Units
Shares / value
93,750
Estimated value
Report date
27 Jun 2022
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

ArriVent BioPharma, Inc.

Security class
Non-Qualified Stock Option (right to buy)
Shares / value
13,562
Estimated value
Report date
18 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ImmunoGen, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
30 Nov 2023
Price
$29.64
Ownership
Direct
Form 4 holding Director

ImmunoGen, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
12 Feb 2024
Price
$4.56
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Paratek Pharmaceuticals, Inc.

Security class
Stock option (right to buy)
Shares / value
0
Estimated value
Report date
21 Sep 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Kristine Peterson

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .